机构表示，9月—10月是消费电子板块的新品密集发布期，产业链进入量产高峰。产业链相关公司在低 估值位置上有补涨空间，建议关注AI端侧创新带来的投资机会。 另有消息称，OpenAI已与苹果设备代工商立讯精密签署协议，合作打造一款消费级设备。该设备目前 仍处于原型开发阶段，预计将采用口袋便携设计，具备情境感知能力，且专为与ChatGPT母公司（即 Open AI）的人工智能模型深度协同工作而打造。 消费电子概念22日盘中强势拉升，截至发稿，鸿富瀚涨约14%，中科蓝讯、智信精密、聚辰股份等涨超 10%，国光电器、盈趣科技、立讯精密等涨停。 消息面上，Meta上周召开Meta Connect 2025大会，正式发布5款核心硬件新品，包括1款Meta首发的AR 眼镜、3款无显示的AI眼镜，以及1款基于sEMG技术的肌电手环。据XR研究院信息，Meta本次大会战 略性保留了2款已完成开发的AI眼镜产品，预计将于2026年第一季度重磅推出。Meta此次发布的AR眼镜 内部代号为Celeste，该产品最初并未计划采用雷朋联名，但在Meta的甜蜜攻势下，最终获得了陆逊梯卡 的雷朋品牌授权，正式命名为Meta Ray-Ban D ...

Meta的地平线工作室过去一年发布了多款应用生成式人工智能的工具，帮助创作者进行创作。扎克伯格说，该工作室很快将推出"Meta Horizon Engine"（Meta地平线引擎），将所有这些不同的工具整合，并进一步加以利用。 据扎克伯格介绍，这个引擎致力于将元宇宙变得性能更快，加载内容体验更佳，能轻松创建无限连接的虚拟空间。新引擎可以给虚拟空间带来更好的渲染效 果，用户可自定义自己的主页。新引擎对虚拟空间渲染的速度提升，只需要几秒钟，这让创建过程变得更容易。此外，新引擎还可让更多人处于同一个虚拟 空间中，并做更多互动。 扎克伯格称，新的地平线引擎可用AI工具提高虚拟内容创作速度，未来将支持这些内容接入眼镜。 9月18日，Meta发布了其首款带显示的AI眼镜，可实时翻译，支持3K视频录制。Meta创始人扎克伯格重点介绍了新的地平线引擎，它可用AI工具提高虚拟内 容创作速度，未来将支持这些内容接入眼镜。 群智咨询（Sigmaintell）分析师陶扬向第一财经记者表示，Meta在年度大会上发布的AR与AI眼镜新品，包括其首款量产带显示屏和光波导的AI眼镜Ray-Ban Meta Display、两款无显示AI眼镜 ...

Core Viewpoint - The rapid development of brain-computer interface (BCI) technology is leading a new wave of medical revolution, with significant investments and policy support driving the industry forward [1][3][15]. Investment and Financing - Neuralink, founded by Elon Musk, recently completed a $600 million financing round, setting a global record for the BCI sector [1]. - In February, Ladder Medical announced a 350 million yuan Series B financing, marking a record for public financing in China's implanted BCI industry [1]. Regulatory and Policy Support - The National Medical Insurance Administration released guidelines for pricing projects related to neurological medical services, establishing separate pricing standards for invasive and non-invasive BCI technologies [1]. - A series of national and local policies have been introduced to promote the innovation and development of the BCI industry, aiming for breakthroughs in key technologies by 2027 and establishing a competitive industrial ecosystem by 2030 [15][18][19][20][21][22]. Technological Advancements - Changzhou Ruishenan Medical's implanted deep brain stimulation (CNS) system has received approval from the National Medical Products Administration, becoming the third company in China to have a product approved in the invasive BCI field [1][2]. - The CNS system features innovative technologies such as 8-contact electrodes and automatic position sensing, enabling personalized treatment models [2][11]. Clinical Applications - Parkinson's disease, affecting over 10 million patients globally, is a key area for BCI applications, with deep brain stimulation (DBS) technology becoming crucial for mid-to-late stage patients [6]. - Clinical trial results for Ruishenan's system show significant improvements in patients' daily living abilities, with a 57.29% improvement rate in daily living ability and a 59.83% reduction in movement-related complications [6]. Market Potential - According to McKinsey, the global market potential for serious medical applications of BCI is estimated to be between $15 billion and $85 billion, while consumer medical applications could reach $25 billion to $60 billion [3]. Competitive Landscape - The domestic BCI industry is characterized by a diverse competitive landscape, with companies like Ladder Medical, Brain Tiger Technology, and BoRuiKang leading in invasive BCI technology, while non-invasive BCI applications are being explored by companies like Aoyi Technology and QiangNai Technology [8][10][12][13]. Challenges and Future Outlook - Despite the immense potential of BCI technology, challenges such as technical and ethical issues in invasive BCI, as well as the need for streamlined approval processes, remain significant barriers to rapid commercialization [14]. - The introduction of supportive policies and the establishment of a clear roadmap for the next five years are expected to facilitate the transition from laboratory exploration to large-scale application in the BCI industry [17].